TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC).

被引：0
|
作者：
von Minckwitz, G. [1 ]
Cortes, J. [1 ]
Gligorov, J. [1 ]
Marschner, N. W. [1 ]
Puglisi, F. [1 ]
Vrdoljak, E. [1 ]
Duenne, A-A [1 ]
Zielinski, C. [1 ]
机构：
[1] GBG Forsch GmbH, German Breast Grp, Neu Isenburg, Germany
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-OT3-01-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-01-04
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Brodowicz, T.
    Pienkowski, T.
    Beslija, S.
    Melichar, B.
    Lang, I.
    Inbar, M. J.
    Anghel, R.
    Spanik, S.
    Ahlers, S.
    Zielinski, C.
    CANCER RESEARCH, 2013, 73
  • [22] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [23] Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C. C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Zvirbule, Z.
    Steger, G. G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S263 - S264
  • [24] AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
    Pujade-Lauraine, Eric
    Hilpert, Felix
    Weber, Beatrice
    Reuss, Alexander
    Poveda, Andres
    Kristensen, Gunnar
    Sorio, Roberto
    Vergote, Ignace B.
    Witteveen, Petronella
    Bamias, Aristotelis
    Pereira, Deolinda
    Wimberger, Pauline
    Oaknin, Ana
    Mirza, Mansoor Raza
    Follana, Philippe
    Bollag, David T.
    Ray-Coquard, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): Final results
    Rugo, H. S.
    Campone, M.
    Amadori, D.
    Wardley, A. M.
    Aldrighetti, D.
    Conte, P. F.
    Liu, D.
    Mudenda, B.
    McHenry, M. B.
    Pivot, X. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts).
    Thomssen, C.
    Pierga, J-Y
    Pritchard, K., I
    Biganzoli, L.
    Cortes-Funes, H.
    Petrakova, K.
    Kaufman, B.
    Smith, I. E.
    CANCER RESEARCH, 2009, 69 (24) : 854S - 854S
  • [27] Phase II trial evaluating the combination of eribulin (E) plus bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
    Hardy-Bessard, A-C.
    Brocard, F.
    Leheurteur, M.
    Melis, A.
    Dauba, J.
    Lortholary, A.
    You, B.
    Guardiola, E.
    Grenier, J.
    Martin-Babau, J.
    Meunier, J.
    Follana, P.
    Savoye, A-M.
    Mercier-Blas, A.
    Marti, A.
    Despax, R.
    Barbier, N.
    Gane, N.
    Ardisson, P.
    Segura-Djezzar, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] UPDATED RESULTS FROM A LARGE, MULTICENTRE STUDY OF 1ST-LINE BEVACIZUMAB (BEV) COMBINED WITH PACLITAXEL (PAC) FOR HER2-NEGATIVE METASTATIC BREAST CANCER (MBC) IN ROUTINE ONCOLOGY PRACTICE
    Foerster, F.
    Schneeweiss, A.
    Geberth, M.
    Tesch, H.
    Klare, P.
    Kuemmel, S.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 104 - 105
  • [29] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.
    Lang, I.
    Inbar, M. J.
    Greil, R.
    Steger, G. G.
    Beslija, S.
    Kahan, Z.
    Eniu, A. E.
    Zvirbule, Z.
    Sirbu, D. E.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Multinational study (n=2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391
    Cortes-Funes, H.
    Pritchard, K. I.
    Biganzoli, L.
    Thomssen, C.
    Pierga, J.
    Koza, I.
    Kwong, A.
    Kellokumpu-Lehtinen, P.
    Chlistalla, A.
    Smith, I.
    EJC SUPPLEMENTS, 2009, 7 (02): : 265 - 266
12345